Published in Pain and Central Nervous System Week, August 28th, 2006
"Because raised matrix metalloprotease (MMP) levels are associated with glioma invasion and angiogenesis, we tested the efficacy of MT, an orally active drug that can reduce MMP levels, in patients with gliomas. A total of 162 patients with intracranial glioblastoma multiforme or gliosarcomas who had undergone surgery and radiotherapy participated in this multicenter, double-blind, placebo-controlled, parallel group study conducted at 20 institutions," scientists in the United States report.
"Seventy-nine patients (57 male, 22 female, median age 58 years) were...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pain and Central Nervous System Week